Holen Sie sich die Stockscreener-App
8.70
0.23%
0.02
Handel nachbörslich:
8.74
0.04
+0.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.68
Offen:
$8.59
24-Stunden-Volumen:
5.80M
Relative Volume:
1.02
Marktkapitalisierung:
$1.39B
Einnahmen:
$793.74M
Nettoeinkommen (Verlust:
$-398.71M
KGV:
-1.1983
EPS:
-7.26
Netto-Cashflow:
$-514.43M
1W Leistung:
-4.50%
1M Leistung:
+7.94%
6M Leistung:
-38.12%
1J Leistung:
+77.19%
1-Tages-Spanne:
$8.37
$8.8877
1-Wochen-Bereich:
$8.37
$9.75
52-Wochen-Spanne:
$3.5324
$23.86
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Vergleichen Sie NVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.70 | 1.39B | 793.74M | -398.71M | -514.43M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines - MSN
Novavax Inc. stock rises Friday, still underperforms market - MarketWatch
Peering Into Novavax's Recent Short Interest - Benzinga
(NVAX) Trading Advice - Stock Traders Daily
Wellington Management Group LLP Makes New $923,000 Investment in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax adjusts vaccine deal with Australian government - Investing.com
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Barclays PLC Raises Stock Position in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth - Simply Wall St
Novavax, Inc. (NASDAQ:NVAX) Shares Acquired by State Street Corp - MarketBeat
Notable Monday Option Activity: AVAV, NKE, NVAX - Nasdaq
Adult Vaccines Market Generated Opportunities, Future Scope - openPR
Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Tidal Investments LLC - MarketBeat
Novavax Earns $50 Million from Sanofi Partnership - Precision Vaccinations
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone - Quantisnow
Novavax to Participate in Jefferies London Healthcare Conference - The Eastern Progress Online
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024? - Investor's Business Daily
Novavax achieves $50M milestone in Sanofi partnershi - Investing.com
Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? - Yahoo Finance
Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% - Yahoo Finance
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online
Novavax Inc. stock rises Wednesday, still underperforms market - MarketWatch
Novavax to Participate in Upcoming September Conferences - The Eastern Progress Online
Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - Quantisnow
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - MSN
Novavax starts Phase 3 trial for dual COVID-19/flu vaccine - Investing.com
Novavax Launches Phase 3 Trial for Revolutionary COVID-Flu Combo Vaccine in Elderly Population - StockTitan
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. - The Eastern Progress Online
Cramer's Lightning Round: 'I'm not a fan of Novavax' - CNBC
Two Sigma Advisers LP Grows Stake in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Novavax, Inc. (NASDAQ:NVAX) Holdings Lowered by BNP Paribas Financial Markets - MarketBeat
Charles Schwab Investment Management Inc. Boosts Stock Position in Novavax, Inc. (NASDAQ:NVAX) - MarketBeat
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial - The Eastern Progress Online
Novavax (NASDAQ:NVAX) Trading 10.1% HigherShould You Buy? - MarketBeat
Stock Traders Buy High Volume of Novavax Call Options (NASDAQ:NVAX) - MarketBeat
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt - Benzinga
FY2024 EPS Estimates for Novavax Decreased by Zacks Research - MarketBeat
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. - The Eastern Progress Online
Noteworthy Friday Option Activity: NVAX, MTDR, MU - Nasdaq
Protecting Life-Saving IP: Novavax Strengthens Security with Threat Intelligence-Driven Security - Recorded Future
Novavax (NVAX) Shares Surge as Czech Facility Sold to Novo Nordi - GuruFocus.com
Institutional investors may overlook Novavax, Inc.'s (NASDAQ:NVAX) recent US$51m market cap drop as long-term gains remain positive - Simply Wall St
Novavax Inc. stock remains steady Thursday, still outperforms market - MarketWatch
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M - Yahoo Finance
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell? - Yahoo! Voices
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors - AOL
Novo expands EU footprint with $200m Novavax plant - BioProcess Insider
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):